Frontlight ResearchEarly access
Active, not recruitingPhase 3
Multicenter, randomized, double-blind, Phase III study of intravenous TAD® 600 mg/4 ml solution for injection to evaluate efficacy and safety in preventing myocardial injury in patients with pneumonia
Key facts
- Who runs it
- Biomedica Foscama Industria Chimico-Farmaceutica S.p.A.
- Where
- Italy7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 178 people, planned
- Started
- 7 May 2024
- Ended
- 1 Nov 2024
- Type of study
- Interventional
- Record updated
- 25 June 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Patients with an age of ≥ 18 and ≤ 85 years
- Diagnosis of CAP or HAP requiring hospitalization
- Patients with one of the following (a or b*): a. At least one cardiovascular comorbidity: • Chronic atrial fibrillation • History of ischemic heart disease (≥ 3 months) • History of heart failure (NYHA class I e II) • Cardiac Valvular Disease • Previous (≥ 2 months) episode of myocarditis or pericarditis b. Very high risk of developing cardiovascular diseases according to the SCORE2 and SCORE2-OP risk models for moderate risk European regions (score ≥ 7.5% for patients 40-50 years old, score ≥ 10% for patients 50-69 years old, and score ≥ 15% for patients ≥ 70 years old). * Please note that if the patient meets inclusion criterion 3(a), the CVD risk should not be calculated
- Provision of written informed consent as approved by the Ethics Committee (EC) by the patient or his/her legal representative
Who cannot take part
- Use of drugs containing sacubitril
- Use of drugs with antioxidant activity in the last 3 months
- Participation in other investigational drug or device clinical trials within 30 days prior to study screening
- History of hypersensitivity to glutathione or any excipients
- Recent (< 1 month) myocardial revascularization
- History of severe heart failure (NYHA class III and IV)
- History of severe liver disease
- Severe to end-stage renal failure (eGFR < 30 mL/min)
- Active malignancy with a life expectancy < 2 years
- Routine use or abuse of narcotics
- Use of invasive mechanical ventilation
- Patients unable or unwilling to comply with the appointments after hospitalization or with all the requirements of the Protocol
- Women of child-bearing potential not using at least one effective contraceptive method for the entire trial
- Pregnant or breastfeeding women
- Women of child-bearing potential not using at least one effective contraceptive method for the entire trial
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
TAD® used as an add-on treatment, due to the presence of the sodium salt glutathione, could be effective and safe in preventing myocardial injury in hospitalized patients with pneumonia.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 25 June 2025